ERS Genomics appoints vice-president of IP
ERS Genomics, the company that provides access to CRISPR/Cas9 IP owned by researcher Emmanuelle Charpentier, has appointed Michael Arciero as vice-president of IP and commercial development.
With more than 15 years of experience in corporate and academic transactions, Arciero will oversee the company’s IP portfolio and become a member of ERS Genomics’ business development team.
Eric Rhodes, CEO of ERS Genomics, said: “Michael brings a strong background not only in IP matters, but also in structuring deals with a wide range of companies. He will be a key asset in our global expansion efforts, focused on widespread adoption and use of CRISPR/Cas9 across industries including life sciences, veterinary science, and industrial chemicals.”
He previously served as director of technology commercialisation and new ventures for the USC Stevens Center for Innovation, the technology transfer office for the University of Southern California.
At the university, he led the technology transfer and corporate alliance teams in supporting innovation across all disciplines.
Arciero said: “The CRISPR/Cas9 system has already led to important research breakthroughs and we've only scratched the surface of what is possible. I'm excited to join ERS and help advance the company’s mission to increase global commercial access to this revolutionary technology.”
Did you enjoy reading this story? Sign up to our free daily newsletters and get stories sent like this straight to your inbox.